#### Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

#### REGENERON PHARMACEUTICALS INC

Form 4

March 22, 2013

# FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB** Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

**OMB APPROVAL** 

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* **BROWN MICHAEL S** 

(First)

(Street)

(Middle)

2. Issuer Name and Ticker or Trading

Symbol

REGENERON

PHARMACEUTICALS INC

[REGN]

3. Date of Earliest Transaction

(Month/Day/Year) 03/21/2013

\_X\_\_ Director Officer (give title

Issuer

10% Owner \_ Other (specify

777 OLD SAW MILL RIVER ROAD

(Last)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

5. Relationship of Reporting Person(s) to

(Check all applicable)

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

TARRYTOWN, NY 10591

(City)	(State)	(Zip) Tab	le I - Non-I	Derivative	Secu	rities Acqu	ired, Disposed of	, or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securi on(A) or D (Instr. 3,	ispose 4 and (A) or	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/21/2013		M(1)	2,000	A	\$ 18.61	16,662	D	
Common Stock	03/21/2013		S <u>(1)</u>	2,000	D	\$ 174.13 (2)	14,662	D	
Common Stock	03/21/2013		M(1)	3,000	A	\$ 18.61	17,662	D	
Common Stock	03/21/2013		S(1)	3,000	D	\$ 173.31	14,662	D	

### Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

					(3)		
Common Stock	03/21/2013	M <u>(1)</u>	6,760	A	\$ 18.61	21,422	D
Common Stock	03/21/2013	S <u>(1)</u>	6,760	D	\$ 173.31 (4)	14,662	D
Common Stock	03/21/2013	M <u>(1)</u>	3,240	A	\$ 18.61	17,902	D
Common Stock	03/21/2013	S <u>(1)</u>	3,240	D	\$ 172.61 (5)	14,662	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number on Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou or Numb of Shares
Non-Qualified Stock Option (right to buy)	\$ 18.61	03/21/2013		M <u>(1)</u>	2,000	<u>(6)</u>	01/02/2019	Common Stock	2,00
Non-Qualified Stock Option (right to buy)	\$ 18.61	03/21/2013		M <u>(1)</u>	3,000	<u>(6)</u>	01/02/2019	Common Stock	3,00
Non-Qualified Stock Option (right to buy)	\$ 18.61	03/21/2013		M <u>(1)</u>	6,760	<u>(6)</u>	01/02/2019	Common Stock	6,76
Non-Qualified Stock Option (right to buy)	\$ 18.61	03/21/2013		M(1)	3,240	<u>(6)</u>	01/02/2019	Common Stock	3,24

(e.g., puts, calls, warrants, options, convertible securities)

## **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

BROWN MICHAEL S
777 OLD SAW MILL RIVER ROAD X
TARRYTOWN, NY 10591

### **Signatures**

/s/\*\*Michael S.

Brown 03/22/2013

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- Represents volume-weighted average price of sales of 2,000 shares of Company stock on March 21, 2013 at prices ranging from \$174.00 (2) to \$174.64. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 21, 2013 at each separate price.
- Represents volume-weighted average price of sales of 3,000 shares of Company stock on March 21, 2013 at prices ranging from \$173.00 (3) to \$173.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 21, 2013 at each separate price.
- Represents volume-weighted average price of sales of 6,760 shares of Company stock on March 21, 2013 at prices ranging from \$173.00 (4) to \$173.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 21, 2013 at each separate price.
- Represents volume-weighted average price of sales of 3,240 shares of Company stock on March 21, 2013 at prices ranging from \$172.11 (5) to \$172.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 21, 2013 at each separate price.
- (6) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
- (7) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3